Amendments to the Claims

1. (Currently Amended) A compound of formula (I):-



(I)

such that Ar is an aryl or a heteroaryl, and the  is beta to the  on the aryl,

wherein:-

====== is a single or a double bond;

R^1 and R^2 are each independently hydrogen or lower alkyl;

R^3 is aryl, arylalkenyl, cycloalkenyl, cycloalkyl, heteroaryl, heteroarylalkenyl, heterocycloalkenyl, a carbon linked heterocycloalkyl or alkyl optionally substituted by one or more groups selected from hydroxy, alkoxy, alkyloxycarbonylamino, cycloalkyl, heterocycloalkyl, R^6, $-OR^6$, $-S(O)_mR^6$ or $-C(=O)-R^6$;

R^4 is hydrogen, acyl, alkoxy, alkyloxycarbonyl, carboxy, cyano, halo, hydroxy, $-C(=O)-NY^1Y^2$ or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, hydroxy, $-S(O)_m$-alkyl or $-NY^1Y^2$;

R^6 is aryl or heteroaryl;

Y^1 and Y^2 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl, heteroarylalkyl or heterocycloalkyl; or the group $-NY^1Y^2$ may form a cyclic amine;

m is zero or an integer 1 to 2; and

n is 2 ~~zero or an integer 1 to 4~~; or

an N-oxide of said compound, a prodrug of said compound, a pharmaceutically acceptable salt of said compound, a solvate of said compound, or a hydrate of said compound.

2. (Currently Amended) The compound of Claim 1, wherein R^1 or R^2 is hydrogen, or R^1 and R^2 are hydrogen, and R^3 is an aryl or ~~an~~ a heteroaryl.

3. (Previously Presented) The compound of Claim 2, wherein said R^3 is a phenyl or a naphthyl.

4. (Previously Presented) The compound of Claim 2, wherein said R^3 is aryl substituted with at least one substituent.

5. (Original) The compound of Claim 4, wherein said substituent is selected from the group consisting of a halo atom, an alkyl substituted by aryl, an alkyl substituted by aryloxy, an alkyl substituted by aroyl, an alkyl substituted by heteroaryl, an arylalkynyl, a heteroarylalkynyl, an aryl, a heteroaryl, an arylalkenyl and an arylalkyloxy.

6. (Original) The compound of Claim 5, wherein said aryl or heteroaryl of said substituent is further substituted by at least one aryl group substituent.

7. (Previously Presented) The compound of Claim 2, wherein said heteroaryl is a pyridyl, a quinolinyl, a thienyl, a furanyl, or an indolyl.

8. (Original) The compound of Claim 7, wherein said heteroaryl is substituted with at least one substituent.

9. (Previously Presented) The compound of Claim 8, wherein said substituent is an alkyl, an alkyl substituted by an aryl, an alkyl substituted by an aryloxy, an alkyl substituted by an aroyl, an alkyl substituted heteroaryl, an arylalkynyl, a heteroarylalkynyl, a heteroaryl, an arylalkenyl or an arylalkyoxy.

10. (Original) The compound of Claim 9, wherein said aryl of said substituent is further substituted by at least one aryl substituent.

11. (Previously Presented) The compound of Claim 1, wherein R^4 is hydrogen or a cyano group.

12. (Previously Presented) The compound of Claim 1, wherein R^5 is a hydrogen, a lower alkyl, or a halo.

13. (Cancelled).

14. (Cancelled).

15. (Currently Amended) The compound of Claim 1, wherein:

Ar is a phenyl group;

R^1 and R^2 are both hydrogen;

R^3 is an aryl, a naphthyl or a heteroaryl;

R^4 is hydrogen or a cyano; and

------ is a single bond; ~~and~~

~~n=2~~.

16. (Previously Presented) The compound of Claim 15, wherein R^3 as aryl or naphthyl is substituted with at least one substituent selected from the group consisting of a halo atom, an alkyl substituted by aryl, an alkyl substituted by aryloxy, an alkyl substituted by aroyl, an alkyl substituted by aryloxy, an alkyl substituted by aroyl, an alkyl substituted by a heteroaryl, an arylalkynyl, a heteroarylalkynyl, an aryl, a heteroaryl, an arylalkenyl, and an arylalkyloxy.

17. (Original) The compound of Claim 16, wherein said aryl or said heteroaryl of said substituent is further substituted by at least one aryl substituent.

18. (Previously Presented) The compound of Claim 15, wherein R^3 as heteroaryl is substituted by at least one substituent selected from the group consisting of a pyridyl, a quinolinyl, a thienyl a furanyl, ~~or~~ and an indolyl.

19. (Previously Presented) The compound of Claim 18, wherein said substituent of said heteroaryl is further substituted by at least one moiety selected from the group consisting of an alkyl substituted by an aryl, an alkyl substituted by an aryloxy, an alkyl substituted by an aroyl, an alkyl substituted heteroaryl, an arylalkynyl, a heteroarylalkynyl, a heteroaryl, an arylalkenyl, and an arylalkyloxy.

20. (Original) The compound of Claim 19, wherein an aryl of said moiety is further substituted by at least one aryl substituent.

21. (Currently Amended) A compound of formula (Ia):



(Ia)

wherein

R^1 and R^2 are each independently hydrogen or lower alkyl;

R^3 is aryl, arylalkenyl, cycloalkenyl, cycloalkyl, heteroaryl, heteroarylalkenyl, heterocycloalkenyl, a carbon linked heterocycloalkyl or alkyl optionally substituted by one or more groups selected from hydroxy, alkoxy, alkyloxycarbonylamino, cycloalkyl, heterocycloalkyl, R^6, $-OR^6$, $-S(O)_mR^6$ or $-C(=O)-R^6$;

R^4 is hydrogen, acyl, alkoxy, alkyloxycarbonyl, carboxy, cyano, halo, hydroxy, $-C(=O)-NY^1Y^2$ or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, hydroxy, $-S(O)_m$-alkyl or $-NY^1Y^2$;

R^5 is hydrogen, acyl, alkoxy, alkyloxycarbonyl, aryl, carboxy, cyano, halo, heteroaryl, heteroaryloxy, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylalkyloxy, heteroarylalkyloxy, hydroxy, trifluoromethyl, $-C(=O)-NY^1Y^2$, $-NY^1Y^2$, $-Z^1-C_{2-6}$alkylene-R^7 or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, aryl, heteroaryl, heterocycloalkyl, hydroxy, ureido, $-C(=O)-NY^1Y^2$, $-SO_2-NY^1Y^2$, $-S(O)_m$-alkyl or $-NY^1Y^2$, and

R^6 is aryl or heteroaryl;

R^7 is hydroxy, alkoxy, ureido, $-C(=O)-NY^1Y^2$, $-SO_2-NY^1Y^2$, $-S(O)_m$-alkyl or $-NY^1Y^2$,

R^8 is hydrogen or lower alkyl;

Y^1 and Y^2 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl, heteroarylalkyl or heterocycloalkyl; or the group $-NY^1Y^2$ may form a cyclic amine;

Z^1 is O, $S(O)_m$ or NR^8;

m is zero or an integer 1 to 2; and

n is 2 ~~zero or an integer 1 to 4~~; or

an N-oxide of said compound, a prodrug of said compound, a pharmaceutically acceptable salt of said compound, a solvate of said compound, an N-oxide of said solvate of said compound, or a prodrug of said solvate of said compound.

22. (Previously Presented) The compound of Claim 21, wherein R^3 is a phenyl or a naphthyl.

23. (Previously Presented) The compound of Claim 22, wherein said aryl is substituted by at least one substituent selected from the group consisting of a halo atom, an alkyl substituted by an aryl, and an alkyl substituted by a heteroaryl.

24. (Original) The compound of Claim 23, wherein said aryl or heteroaryl of said substituent is further substituted by at least one aryl group substituent.

25. (Previously Presented) The compound of Claim 21, wherein R^3 is phenylC_{1-3}alkylpyridyl, phenylC_{1-3}alkylthienyl or indolyl.

26. (Previously Presented) The compound of Claim 21, wherein R^3 is a heteroaryl selected from the group consisting of a pyridyl, a quinolinyl, a thienyl, a furanyl, and an indolyl.

27. (Previously Presented) The compound of Claim 26, wherein said heteroaryl is substituted by at least one substituent selected from the group consisting of an alkyl substituted by an aryl, and an alkyl substituted by a heteroaryl.

28. (Original) The compound of Claim 27, wherein said aryl and said heteroaryl of said substituent are further substituted by at least one aryl group substituent.

29. (Previously Presented) The compound of Claim 28, wherein R^3 is phenylC_{1-3}alkylpyridyl, phenylC_{1-3}alkylthienyl or indolyl.

30. (Previously Presented) The compound of Claim 21, wherein R^4 is a hydrogen or a cyano.

31. (Previously Presented) The compound of Claim 21, wherein R^5 is a hydrogen, a lower alkyl or a halo.

32. (Previously Presented) The compound of Claim 31, wherein R^5 is methyl or fluoro.

33. (Original) The compound of Claim 31, wherein R^5 is attached to the phenyl ring of formula (Ia) in the position para to the CH_2NH_2 group.

34. (Previously Presented) The compound of Claim 21, wherein:
R^3 is a phenyl, a naphthyl, a heteroaryl selected from the group consisting a pyridyl, a quinolinyl, a thienyl, a furanyl, and an indolyl, a phenyl substituted by at least one substituent, a naphthyl substituted by at least one substituent, or a heteroaryl selected from the group consisting a pyridyl, a quinolinyl, a thienyl, a furanyl, and an indolyl, that is substituted by at least one substituent,

wherein said substituent is selected from the group consisting of a halo atom, an alkyl substituted by aryl, and alkyl substituted heteroaryl, wherein the aryl or heteroaryl groups are further substituted by one or more aryl group substituents;

R^4 is hydrogen or a cyano; and

R^5 is hydrogen, a lower alkyl or a halo.

35. (Previously Presented)The compound of Claim 34, wherein:

R^3 is phenylC_{1-3}alkylpyridyl, phenylC_{1-3}alkylthienyl or indolyl;

R^4 is a hydrogen or a cyano; and

R^5 is a methyl or a fluoro, and is attached to the phenyl ring of formula(Ia) in the position para to the $CR^1R^2NH_2$ group.

36. (Previously Presented) The compound of Claim 21, having formula (Ib):


(Ib).

37. (Previously Presented) The compound of Claim 36, wherein R^3 as is selected from the group consisting of a phenyl and a naphthyl.

38. (Previously Presented) The compound of Claim 37, wherein said aryl is substituted by at least one substituent selected from the group consisting of a halo atom, an alkyl substituted by an aryl, and an alkyl substituted by a heteroaryl.

39. (Original) The compound of Claim 38, wherein said aryl or heteroaryl of said substituent is further substituted by at least one aryl group substituent.

40. (Previously Presented) The compound of Claim 36, wherein R^3 is a pyridyl, a quinolinyl, a thienyl, a furanyl, or an indolyl.

41. (Previously Presented) The compound of Claim 41, wherein said heteroaryl is substituted by at least one substituent selected from the group consisting of an alkyl substituted by an aryl, ~~or~~ and an alkyl substituted by a heteroaryl.

42. (Original) The compound of Claim 42, wherein said aryl and said heteroaryl of said substituent are further substituted by at least one aryl group substituent.

43. (Previously Presented) The compound of Claim 36, wherein R^3 is phenylC_{1-3}alkylpyridyl, phenylC_{1-3}alkylthienyl or indolyl.

44. (Previously Presented) The compound of Claim 36, wherein R^4 is a hydrogen or a cyano.

45. (Previously Presented) The compound of Claim 36, wherein R^5 is a hydrogen, a lower alkyl or a halo.

46. (Previously Presented) The compound of Claim 45, wherein R^5 is a methyl or a fluoro.

47. (Original) The compound of Claim 45, wherein R^5 is attached to the phenyl ring of formula (Ib) in the position para to the CH_2NH_2 group.

48. (Previously Presented) The compound of Claim 36, wherein:
R^3 is a phenyl, a naphthyl, a heteroaryl selected from the group consisting a pyridyl, a quinolinyl, a thienyl, a furanyl, and an indolyl, a phenyl substituted by at least one substituent, a naphthyl substituted by at least one substituent, or a heteroaryl selected from the group consisting a pyridyl, a quinolinyl, a thienyl, a furanyl, and an indolyl, that is substituted by at least one substituent,

wherein said substituent is selected from the group consisting of a halo atom, an alkyl substituted by aryl, and alkyl substituted heteroaryl, wherein the aryl or heteroaryl groups are further substituted by one or more aryl group substituents;

R^4 is hydrogen or a cyano; and

R^5 is hydrogen, a lower alkyl or a halo.

49. (Previously Presented) The compound of Claim 48, wherein:

R^3 is phenylC_{1-3}alkylpyridyl, phenylC_{1-3}alkylthienyl or indolyl;

R^4 is a hydrogen or a cyano; and

R^5 is a methyl or a fluoro.

50. (Original) The compound of Claim 1, selected from the group consisting of:
3-[1-(5-phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;
3-[1-(3-phenylethyl-benzoyl)-piperidin-4-yl]-benzylamine;
3-{1-[3-(4-hydroxyphenyl)ethyl-benzoyl]-piperidin-4-yl}-benzylamine;
3-{1-[3-(6-amino-pyridin-3-yl)ethyl-benzoyl]-piperidin-4-yl}-benzylamine;
3-[1-(5-phenylethyl-thiophene-2-carbonyl)-piperidin-4-yl]-benzylamine;
4-fluoro-3-[1-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;
4-methyl-3-[1-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;
3-[1-(indole-6-carbonyl)-piperidin-4-yl]-benzylamine;
4-(3-aminomethyl-phenyl)-1-(5-phenethyl-pyridine-3-carbonyl)-piperidine-4-carbonitrile
[4-(3-aminomethylphenyl)piperidin-1-yl]-(3,4-dichlorophenyl)methanone;

1-{1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl}-3-methylsulfanyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;

1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(3-methylsulfanyl-6,7-dihydro-benzo[c]thiophen-1-yl)-methanone trifluoroacetate;

1-{1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl}-3-ethylsulfanyl-6,6-dimethyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;

1-{1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl}-3-propylsulfanyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;

1-{1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl}-3-isopropylsulfanyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;

1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-benzo[b]thiophen-2-yl-methanone-trifluoroacetate;

1-[4-(3-Aminomethyl-phenyl)-4-hydroxy-piperidin-1-yl]-1-(5-phenethyl-pyridin-3-yl)-methanone-ditrifluoroacetate;

1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(1-methyl-1H-indol-3-yl)-methanone-trifluoroacetate;

1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-[3-(2-fluoro-phenylethynyl)-phenyl]-methanone trifluoroacetate;

1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-{3-[2-(2-fluoro-phenyl)-ethyl]-phenyl}-methanone trifluoroacetate;

1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-{3-[2-(6-amino-pyridin-3-yl)-ethyl]-phenyl}-methanone tri-trifluoroacetate;

1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(6-chloro-thieno[3,2-*b*]thiophen-2-yl)-methanone trifluoroacetate;

(3R,4S) and (3S, 4R)-4-(3-Aminomethyl-phenyl)-1-(5-phenethyl-pyridine-3-carbonyl)-piperidine-3-carboxylic acid ethyl ester dihydrochloride;

3-[1-(5-Phenylethynyl-furan-2-carbonyl)-piperidin-4-yl]-benzylamine trifluoroacetate;

4-(3-Aminomethyl-phenyl)-piperidine-1-carboxylic acid (3,4-dichloro-phenyl)-amide trifluoroacetate;

1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(2,3-dihydro-benzofuran-5-yl)-methanone;

1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(5,6-dichloro-pyridin-3-yl)-methanone;

1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(3-bromo-4-fluoro-phenyl)-methanone;

(E)-1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-3-(2-nitro-phenyl)-propenone;

1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(3-bromo-5-iodo-phenyl)-methanone; and

(E)-1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-3-phenyl-propenone.

51. (Currently Amended) A pharmaceutical composition comprising a ~~pharmaceutically acceptable~~ therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier thereof.

52. (Original) The pharmaceutical composition of Claim 51, wherein said compound is selected from the group consisting of:
3-[1-(5-phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;
3-[1-(3-phenylethyl-benzoyl)-piperidin-4-yl]-benzylamine;
3-{1-[3-(4-hydroxyphenyl)ethyl-benzoyl]-piperidin-4-yl}-benzylamine;
3-{1-[3-(6-amino-pyridin-3-yl)ethyl-benzoyl]-piperidin-4-yl}-benzylamine;
3-[1-(5-phenylethyl-thiophene-2-carbonyl)-piperidin-4-yl]-benzylamine;
4-fluoro-3-[1-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;
4-methyl-3-[1-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;
3-[1-(indole-6-carbonyl)-piperidin-4-yl]-benzylamine;
4-(3-aminomethyl-phenyl)-1-(5-phenethyl-pyridine-3-carbonyl)-piperidine-4-carbonitrile
[4-(3-aminomethylphenyl)piperidin-1-yl]-(3,4-dichlorophenyl)methanone;
1-{1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl}-3-methylsulfanyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(3-methylsulfanyl-6,7-dihydro-benzo[c]thiophen-1-yl)-methanone trifluoroacetate;
1-{1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl}-3-ethylsulfanyl-6,6-dimethyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;
1-{1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl}-3-propylsulfanyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;
1-{1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl}-3-isopropylsulfanyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-benzo[b]thiophen-2-yl-methanone-trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-4-hydroxy-piperidin-1-yl]-1-(5-phenethyl-pyridin-3-yl)-methanone-ditrifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(1-methyl-1H-indol-3-yl)-methanone-trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-[3-(2-fluoro-phenylethynyl)-phenyl]-methanone trifluoroacetate;

1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-{3-[2-(2-fluoro-phenyl)-ethyl]-phenyl}-methanone trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-{3-[2-(6-amino-pyridin-3-yl)-ethyl]-phenyl}-methanone tri-trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(6-chloro-thieno[3,2-*b*]thiophen-2-yl)-methanone trifluoroacetate;
(3R,4S) and (3S, 4R)-4-(3-Aminomethyl-phenyl)-1-(5-phenethyl-pyridine-3-carbonyl)-piperidine-3-carboxylic acid ethyl ester dihydrochloride;
3-[1-(5-Phenylethynyl-furan-2-carbonyl)-piperidin-4-yl]-benzylamine trifluoroacetate;
4-(3-Aminomethyl-phenyl)-piperidine-1-carboxylic acid (3,4-dichloro-phenyl)-amide trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(2,3-dihydro-benzofuran-5-yl)-methanone;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(5,6-dichloro-pyridin-3-yl)-methanone;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(3-bromo-4-fluoro-phenyl)-methanone;
(E)-1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-3-(2-nitro-phenyl)-propenone;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(3-bromo-5-iodo-phenyl)-methanone;
(E)-1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-3-phenyl-propenone; and
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-3-cyclohexyl-propan-1-one.

53. (Currently Amended) A pharmaceutical composition comprising a ~~pharmaceutically acceptable~~ therapeutically effective amount of a compound of Claim 21 and a pharmaceutically acceptable carrier thereof.

54. (Currently Amended) A pharmaceutical composition comprising a ~~pharmaceutically acceptable~~ therapeutically effective amount of a compound of Claim 36 and a pharmaceutically acceptable carrier thereof.

55. (Currently Amended) A method for treating asthma in a patient ~~comprises~~ comprising administering to the patient a ~~pharmaceutically~~ therapeutically effective amount of a compound of Claim 1.

56. (Cancelled)

57. (Cancelled)

58. (Currently Amended) A method for treating asthma in a patient ~~comprises~~ comprising administering to the patient a ~~pharmaceutically~~ therapeutically effective amount of a compound of Claim 21.

59. (Cancelled)

60. (Cancelled)

61. (Currently Amended) A method for treating asthma in a patient ~~comprises~~ comprising administering to the patient a ~~pharmaceutically~~ therapeutically effective amount of a compound of Claim 36.

62. (Cancelled)

63. (Cancelled)

64. (Withdrawn) A pharmaceutical composition comprising a compound of Claim 1 and a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent; and a pharmaceutically acceptable carrier thereof.

65. (Withdrawn) The pharmaceutical composition of Claim 64, wherein the beta andrenergic agonist comprises albuterol, terbutaline, formoterol, fenoterol or prenaline;

the anticholinergic comprises ipratropium bromide;

the anti-inflammatory corticosteroid comprises beclomethasone dipropionate, triamcinolone acetonide, flunisolide or dexamethasone; and

the anti-inflammatory agent comprises sodium cromoglycate or nedocromil sodium.

66. (Withdrawn) A pharmaceutical composition comprising a compound of formula 21 and a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent; and a pharmaceutically acceptable carrier thereof.

67. (Withdrawn) The pharmaceutical composition of Claim 66, wherein the beta andrenergic agonist comprises albuterol, terbutaline, formoterol, fenoterol or prenaline;

the anticholinergic comprises ipratropium bromide;

the anti-inflammatory corticosteroid comprises beclomethasone dipropionate, triamcinolone acetonide, flunisolide or dexamethasone; and

the anti-inflammatory agent comprises sodium cromoglycate or nedocromil sodium.

68. (Withdrawn) A pharmaceutical composition comprising a compound Claim 36 and a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent; and a pharmaceutically acceptable carrier thereof.

69. (Withdrawn) The pharmaceutical composition of Claim 66, wherein the beta andrenergic agonist comprises albuterol, terbutaline, formoterol, fenoterol or prenaline;

the anticholinergic comprises ipratropium bromide;

the anti-inflammatory corticosteroid comprises beclomethasone dipropionate, triamcinolone acetonide, flunisolide or dexamethasone; and

the anti-inflammatory agent comprises sodium cromoglycate or nedocromil sodium.

70. (Withdrawn) A method for treating a patient suffering from asthma, comprising administering to the patient a combination of a compound of Claim 1, and a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent

71. (Withdrawn) A method for treating a patient suffering from asthma, comprising administering to the patient a combination of a compound of Claim 21, and a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent.

72. (Withdrawn) A method for treating a patient suffering from asthma, comprising administering to the patient a combination of a compound of Claim 36, and a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent.

73. (Previously Presented) The compound of Claim 25, wherein the phenylC_{1-3}alkylpyridyl is 5-phenylethyl-pyrid-3-yl, the phenylC_{1-3}alkylthienyl is and the indolyl is indol-6-yl.

74. (Previously Presented) The compound of Claim 29, wherein the phenylC_{1-3}alkylpyridyl is 5-phenylethyl-pyrid-3-yl, the phenylC_{1-3}alkylthienyl is 5-phenylethyl-thien-2-yl and the indolyl is indol-6-yl.

75. (Previously Presented) The compound of Claim 35, wherein the phenylC_{1-3}alkylpyridyl is 5-phenylethyl-pyrid-3-yl, the phenylC_{1-3}alkylthienyl is 5-phenylethyl-thien-2-yl and the indolyl is indol-6-yl.

76. (Previously Presented) The compound of Claim 1, wherein  is a single bond.